- Home
- SLGL
as 09-13-2024 10:35am EST
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
| Founded: | 1997 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 18.3M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 222.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $2.46 | Next Earning Date: | 11-07-2024 |
| Revenue: | $6,559,000 | Revenue Growth: | 422.21% |
| Revenue Growth (this year): | 457.85% | Revenue Growth (next year): | -3.65% |
Latest Sol-Gel Technologies Ltd. News
SLGL Breaking Stock News: Dive into SLGL Ticker-Specific Updates for Smart Investing
Zacks
20 days ago
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
MT Newswires
a month ago
Top Premarket Decliners
Simply Wall St.
a month ago
Sol-Gel Technologies Second Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
a month ago
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Zacks
a month ago
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
GlobeNewswire
a month ago
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
2 months ago
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
MT Newswires
2 months ago
Sol-Gel Technologies CEO Plans to Step Down; New CFO Named
Compare SLGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLGL Sol-Gel Technologies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.